» Articles » PMID: 38757785

Traditional Chinese Medicine Improved Diabetic Kidney Disease Through Targeting Gut Microbiota

Overview
Journal Pharm Biol
Specialties Pharmacology
Pharmacy
Date 2024 May 17
PMID 38757785
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Diabetic kidney disease (DKD) affects nearly 40% of diabetic patients, often leading to end-stage renal disease that requires renal replacement therapies, such as dialysis and transplantation. The gut microbiota, an integral aspect of human evolution, plays a crucial role in this condition. Traditional Chinese medicine (TCM) has shown promising outcomes in ameliorating DKD by addressing the gut microbiota.

Objective: This review elucidates the modifications in gut microbiota observed in DKD and explores the impact of TCM interventions on correcting microbial dysregulation.

Methods: We searched relevant articles from databases including Web of Science, PubMed, ScienceDirect, Wiley, and Springer Nature. The following keywords were used: diabetic kidney disease, diabetic nephropathy, gut microbiota, natural product, TCM, Chinese herbal medicine, and Chinese medicinal herbs. Rigorous criteria were applied to identify high-quality studies on TCM interventions against DKD.

Results: Dysregulation of the gut microbiota, including , , and , has been observed in individuals with DKD. Key indicators of microbial dysregulation include increased uremic solutes and decreased short-chain fatty acids. Various TCM therapies, such as formulas, tablets, granules, capsules, and decoctions, exhibit unique advantages in regulating the disordered microbiota to treat DKD.

Conclusion: This review highlights the importance of targeting the gut-kidney axis to regulate microbial disorders, their metabolites, and associated signaling pathways in DKD. The Qing-Re-Xiao-Zheng formula, the Shenyan Kangfu tablet, the Huangkui capsule, and the Bekhogainsam decoction are potential candidates to address the gut-kidney axis. TCM interventions offer a significant therapeutic approach by targeting microbial dysregulation in patients with DKD.

Citing Articles

The synergistic role of gut microbiota and RNA in metabolic diseases: mechanisms and therapeutic insights.

Huang Z, Yao Q, Ma S, Zhou J, Wang X, Meng Q Front Microbiol. 2025; 16:1504395.

PMID: 39944642 PMC: 11814227. DOI: 10.3389/fmicb.2025.1504395.


Targeted modulation of intestinal barrier and mucosal immune-related microbiota attenuates IgA nephropathy progression.

Zhang R, Tang Y, Feng X, Lu X, Zhao M, Jin J Gut Microbes. 2025; 17(1):2458184.

PMID: 39875350 PMC: 11776482. DOI: 10.1080/19490976.2025.2458184.


Association of inflammatory cytokines with type 2 diabetes mellitus and diabetic nephropathy: a bidirectional Mendelian randomization study.

Song S, Ni J, Sun Y, Pu Q, Zhang L, Yan Q Front Med (Lausanne). 2024; 11:1459752.

PMID: 39574905 PMC: 11580751. DOI: 10.3389/fmed.2024.1459752.


Diabetic Kidney Disease: Contribution of Phenyl Sulfate Derived from Dietary Tyrosine upon Gut Microbiota Catabolism.

Liu H, Diep T, Wang Y, Wang Y, Yan L Biomolecules. 2024; 14(9).

PMID: 39334919 PMC: 11429668. DOI: 10.3390/biom14091153.

References
1.
Lv Q, Li Z, Sui A, Yang X, Han Y, Yao R . The role and mechanisms of gut microbiota in diabetic nephropathy, diabetic retinopathy and cardiovascular diseases. Front Microbiol. 2022; 13:977187. PMC: 9433831. DOI: 10.3389/fmicb.2022.977187. View

2.
Gryp T, Vanholder R, Vaneechoutte M, Glorieux G . p-Cresyl Sulfate. Toxins (Basel). 2017; 9(2). PMC: 5331431. DOI: 10.3390/toxins9020052. View

3.
Debnath N, Kumar R, Kumar A, Mehta P, Yadav A . Gut-microbiota derived bioactive metabolites and their functions in host physiology. Biotechnol Genet Eng Rev. 2021; 37(2):105-153. DOI: 10.1080/02648725.2021.1989847. View

4.
Su X, Yu W, Liu A, Wang C, Li X, Gao J . San-Huang-Yi-Shen Capsule Ameliorates Diabetic Nephropathy in Rats Through Modulating the Gut Microbiota and Overall Metabolism. Front Pharmacol. 2022; 12:808867. PMC: 8764181. DOI: 10.3389/fphar.2021.808867. View

5.
Wu C, Fei J, Xu Q, Tao Y, Zhou Z, Wang Y . Interaction between Plasma Metabolomics and Intestinal Microbiome in db/db Mouse, an Animal Model for Study of Type 2 Diabetes and Diabetic Kidney Disease. Metabolites. 2022; 12(9). PMC: 9503368. DOI: 10.3390/metabo12090775. View